Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS
Corvus Pharmaceuticals — Technical Presentation (2020)
14 slides from Corvus Pharmaceuticals's technical presentation, Dec 4, 2020
Slide 1: CPI-818, an Oral ITK Inhibitor, is Well-tolerated and Active in Patients with T-Cell Lymphoma
American Society of Hematology 2020, Poster 2068 CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, is Well-tolerated and Active in Patients with T-Cell Lymphoma Michael Khodadoust, MD, PhD Stanford University School of Medicine Michael S. Khodadoust, MD, PhD1, Tatyana A. Feldman, MD2
Slide 2: Disclosures
Disclosures Michael Khodadoust, MD, PhD Kyowa Kirin - Consultant Seattle Genetics – Member of Advisory Board 2
Slide 3: Rationale for Targeting ITK for T Cell Lymphoma
Rationale for Targeting ITK for T Cell Lymphoma T cells TCR § TCR signaling is maintained in most T cell lymphomas CD3/4/8 § Analogous to BCR and B cell lymphomas; ITK is the T cell PIP2 à PIP3 PtdIns(4,5)P2 ITK homologue of BTK and is widely expressed in T cell malignancies LCK P PLCγ Src-family DA
Slide 4: CPI-818 Covalently and Selectively Inhibits ITK
CPI-818 Covalently and Selectivity Inhibits ITK Blocks T Cell Receptor Signaling Pathway Kinome Profile and pPLC𝛄1 Suppression Kinases with Cys-442 0. 1 3 00 00 01 03 CPI-818 (µM): 1 10 0. 0. 0. 0. 0 0 1 TCR 𝝰CD3: – + + + + + + + + CPI-818 Kd in nM pPLC𝛄1 Y783 ITK 2.5 BLK 4700 Total PLC𝛄1…
Slide 5: CPI-818 Preferentially Inhibits Sézary Cells
CPI-818 Preferentially Inhibits Sézary Cells Gating Strategy Inhibition of Cell Division 𝝰CD3/CD28 DMSO DMSO 818 (1 µM) Pt 1 Pt 2 Pt 3 Healthy Donor Proliferation Score TCRV𝝱2+ Total CD4+ Cells TCRV𝝱2- CPI-818 (µM) Proliferation Dye CD8 Cells CD4 Cells Sézary Cells Sézary cells were more…
Slide 6: Spontaneous T Cell Lymphoma in Companion Animals
Spontaneous T Cell Lymphoma in Companion Animals Evaluation of CPI-818 in a dog achieving CR CTCL Patient 11 year old, Male Golden Retriever 4 months 6
Slide 7: CPI-818 Ph 1/1b Clinical Trial Design in T cell Lymphomas
CPI-818 Ph 1/1b Clinical Trial Design in T cell Lymphomas 600mg BID Design 400mg BID • Dose escalation with 3+3 (+ optional 3) design • Ascending dose levels of CPI-818 • Enroll patients with various types of T-cell 200mg BID lymphoma (PTCL and CTCL) who have progressed on, refractory to, relapsed,
Slide 8: CPI-818-001 Study Patient Characteristics
CPI-818-001 Study Patient Characteristics CPI-818 CPI-818 CPI-818 CPI-818 100mg BID 200mg BID 400mg BID 600mg BID Total (N=4) (N=3) (N=5) (N=13) (N=25) Age (yrs), median (range) 51 (29, 75) 59 (57, 60) 69 (42, 80) 62 (34, 84) 62 (29,84) Gender, male N (%) 3 (75%) 0 (0%) 3 (60%) 6 (46.2%) 12 (48%) No
Slide 9: Most Common Adverse Events
Most Common Adverse Events ( ≥ 2 patients) 600mg • No DLTs observed Adverse Events N (%) 100mg (N=4) 200mg (N=3) 400mg (N=5) Total (N=25) (N=13) and MTD not Subjects with any TEAE reached 4 (100.0) 3 (100.0) 4 (80.0) 11 (84.6) 22 (88.0) Fatigue 0 (0.0) 1 (33.3) 3 (60.0) 3 (23.1) 7 (28.0) • Majority
Slide 10: PK and Occupancy Summary from Cohorts 1, 2, and 3
PK and Occupancy Summary from Cohorts 1, 2, 3 and 4 Occupancy is increasing as a function of dose, BID Dosing Required Trough ITK Occupancy for Cycle 1 Plasma CPI-818 and ITK Occupancy in PBMCs with BID Dosing of CPI-818 Following a 100 mg or 600 mg QD Dose 100 100 mg 100 1500 90 200 mg Plasma CPI-8
Slide 11: Summary from the Escalation and Ongoing Expansion in the PTCL-NOS Cohort
Summary from the Escalation and Ongoing Expansion in the PTCL-NOS Cohort Baseline PET Week 30 PET ORR: 1CR, 1PR out of 7 evaluable at doses of ≥ 200 to 600 mg BID PTCL-NOS (2) Histology (PTCL NOS) PTCL-NOS (8) ↓ Target Lesions 200 mg BID PTCL-NOS (5) 600 mg BID PTCL-NOS (4) Ongoing PTCL-NOS (2) SD P
Slide 12: Summary from the Escalation and Ongoing Expansion in the CTCL Cohort
Summary from the Escalation and Ongoing Expansion in the CTCL Cohort CTCL SEZARY (3) CTCL SEZARY (5) Histology (No. of Prior Lines) CTCL SEZARY (7) Skin Improvement CTCL SEZARY (9) CTCL SEZARY (3) 200 mg BID CTCL MYCOSES (9) 400 mg BID CTCL MYCOSES (7) 600 mg BID Ongoing CTCL MYCOSES (8) SD CTCL MYC
Slide 13: Conclusion
Conclusion • CPI-818 is a selective, covalent inhibitor of ITK (sparing RLK and BTK) that blocks signal transduction in endpoints downstream of T-cell activation • The dose-escalation part of the CPI-818-001 trial demonstrated that the 100, 200, 400 and 600 mg BID doses are well tolerated. • 600 mg
Slide 14: Acknowledgements
Acknowledgements Seoul National • Participating Centers and Investigators: University Hospital Asan Medical Center Seoul St Mary Hospital Gachon University Gil Medical Center Hackensack University Samsung Medical United States Medical Center Pusan National University of Michigan South Korea Ohio Sta
Corvus Pharmaceuticals — Technical Presentation (2020) on 6ix